Market Signals Align with Georgia’s Life Sciences Roadmap

A new national outlook on the life sciences real estate market is reinforcing what many in Georgia’s ecosystem have been building toward: a more disciplined, workforce-driven, and manufacturing-focused future for the industry.


CBRE’s 2026 U.S. Life Sciences Market Outlook points to a sector in transition—moving away from rapid, speculative expansion toward a more measured phase defined by targeted growth, capital efficiency, and long-term sustainability.


For Georgia, these trends are not just informative—they are validating.


A Market Reset Creates Opportunity

After several years of rapid expansion in major coastal markets, the national lab space market is recalibrating. Construction has slowed significantly, and vacancy rates—while still elevated—are stabilizing.

This shift favors emerging markets like Georgia that have taken a more measured approach to growth.

Rather than contending with oversupply, Georgia is well-positioned to scale intentionally—aligning infrastructure, workforce, and industry demand in a way that supports long-term success.

 

Manufacturing and Scale-Up Are Driving Growth

One of the clearest signals from the CBRE report is the increasing role of large pharmaceutical and biomanufacturing investments in driving demand.

 

This aligns directly with Georgia’s recent momentum.

 

From major facility expansions to increased interest in onshoring and domestic production, the Southeast—and Georgia in particular—is becoming a destination for advanced manufacturing in the life sciences.

 

The Georgia Life Sciences Roadmap has consistently emphasized this opportunity:

  • Strengthening biomanufacturing capacity
  • Building workforce pipelines to support production scale
  • Positioning Georgia as a hub for both innovation and commercialization

 

Workforce as the Differentiator

As capital becomes more selective and companies prioritize execution, talent—not space—is emerging as the defining constraint.

 

Georgia’s investments in workforce development, including partnerships with the Technical College System of Georgia and the Georgia Bioscience Training Center, position the state to meet this moment.

 

Through coordinated efforts across education, industry, and government, Georgia is building the kind of workforce infrastructure that enables companies to not only locate here—but to grow here.

 

A Converging Ecosystem

Another key trend highlighted in the report is the convergence of life sciences with adjacent sectors such as digital health, robotics, and advanced technologies. This is an area where Atlanta stands out.

 

With strengths in medtech, health IT, and data-driven healthcare solutions, the region offers a broader definition of “life sciences”—one that reflects where the industry is headed, not where it has been.

 

Looking Ahead

The national life sciences sector is entering a new phase—one that rewards strategic alignment, ecosystem coordination, and long-term investment.

 

Georgia is not starting from scratch in this environment. It has been building toward it. The Georgia Life Sciences Roadmap anticipated many of these shifts, prioritizing:

  • Workforce development
  • Manufacturing and scale-up capacity
  • Industry-academic collaboration
  • Capital and commercialization pathways

 

As national trends continue to evolve, Georgia’s focus on disciplined, intentional growth positions the state—and the broader Southeast—as a compelling partner in the next chapter of the life sciences industry.

 

Read report - CBRE Chapter 9, Life Sciences - U.S. Real Estate Market Outlook 2026

https://www.cbre.com/insights/books/us-real-estate-market-outlook-2026/life-sciences

Biotech Leaders Launch National Alliance to Define the Future of American Innovation

May 5, 2026
New coalition forms to develop a national innovation roadmap to strengthen and extend  America’s global leadership in biotechnology

UGA & Manus Among Awardees in $214M BioMADE Investment

April 30, 2026
BioMADE Announces $21.4 Million Invested in 14 Projects to Develop the U.S. Bioindustrial Manufacturing Industry and Advance National Security Priorities

Nutrivert announces first close on $6 million Series A-2 funding round

April 17, 2026
April 17, 2026 - Nutrivert Inc., a developer of non-antibiotic replacements for antibiotic growth promoters in livestock, today announced it has completed the first close, raising $2.375 million, of its Series A-2 funding round of $6 million. The round was led by global animal health investor Arrow Ventures with participation from other investors. The funding will be used to further develop Nutrivert’s manufacturing, human food safety and target animal safety and efficacy packages for the company’s lead product Nutrivert LDPP. Nutrivert LDPP is a proprietary, novel, orally available, lipidated synthetic enantiomeric desmuramyl analog of muramyl dipeptide, the smallest conserved immunoactive component of bacterial peptidoglycan. LDPP has no antibacterial effect but has consistently promoted growth and improved feed efficiency in pig studies. LDPP binds to the mammalian NOD2 receptor and is the only NOD2 ligand reported to inhibit the inflammatory signal NF-κB. In pilot studies, LDPP rescued 70kg pigs from an otherwise lethal dose of porcine reproductive and respiratory syndrome virus (PRRSV) and abrogated influenza disease symptoms in piglets. The Company intends to develop LDPP for all major livestock species worldwide. Patents have been granted in most major markets. The global antibiotic growth promoter market is worth an estimated $5.8 billion. Approximately 73% of all antibiotics are fed to livestock. The market is believed to be the world’s largest drug market by volume, with ~100,000 tons of active pharmaceutical ingredient administered annually. FDA’s latest data, for 2024, show a 13% rise in U.S. livestock antibiotic use since 2017. The Food and Agriculture Organization reports that livestock antibiotics are mostly given to speed animal growth. Regulators and non-governmental organizations have called for reduction of antibiotic use in livestock, citing concerns that the global, intensive use of antibiotics, often at subtherapeutic doses, selects for antimicrobial resistance: bacteria that are “immune” to antibiotics and that therefore pose a threat to public health. Spillovers of antibiotic-resistant bacteria from livestock to humans have been documented. “Nutrivert LDPP has consistently improved feed efficiency in pigs without antibiotics,” said Bernhard Kaltenboeck, CSO. “We are excited to have the support of Arrow Ventures and our other investors in bringing a new tool that will help producers reduce production costs and reduce selection pressure for antimicrobial resistance.” About Nutrivert LDPP: LDPP is an investigational compound currently undergoing clinical evaluation. It has not been approved by the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), or any other global regulatory authority for any indication. The safety and efficacy of LDPP have not been established. Any mention of potential use is based on preliminary data and does not guarantee future regulatory clearance or commercial availability.
MORE POSTS